PLAC™ test for identification of individuals at increased risk for coronary heart disease

Abstract

Recent advances in cardiovascular research point to a critical role of inflammatory processes in the etiology of cardiovascular disease. This has led to the discovery of novel inflammatory biomarkers, which may be useful as additional screening tools for the identification of individuals at increased risk of coronary heart disease. One such novel inflammatory biomarker is lipoprotein-associated phospholipase A₂. This review discusses the recent development of a US Food and Drug Administration-approved blood test for lipoprotein-associated phospholipase A₂ (PLAC™ test, diaDexus, Inc.) and its efficacy as a predictive biomarker of risk for cardiovascular disease. More specifically, the article addresses the potential target group most likely to benefit from this new screening test and provides a prospective scenario for its implementation.

Keywords::

• cardiovascular disease
• inflammatory markers
• lipoprotein-associated phospholipase A2
• suboxidative stress
• PLAC™ test